Video

Dr. Heymach on the Future of Immunotherapy in NSCLC

John V. Heymach, MD, PhD, discusses the future of immunotherapy in patients with non–small cell lung cancer.

John V. Heymach, MD, PhD, chair of Thoracic/Head and Neck Medical Oncology at The University of Texas, MD Anderson Cancer Center, discusses the future of immunotherapy in patients with non–small cell lung cancer (NSCLC).

PD-L1 inhibitors have been thoroughly tested both as monotherapies and in combination regimens, according to Heymach. The use of these agents in patients with this disease has been well established, with monotherapy agents being utilized in those who have a high PD-L1 expression. Combination regimens such as PD-L1 and CTLA-4, particularly nivolumab (Opdivo) plus ipilimumab (Yervoy), have also been explored. For a broader patient population, a combination of PD-1 inhibitors and chemotherapy can be used, Manochakian says.

With this established, future directions for immunotherapy will focus on tailoring treatment decisions based on patient subgroups, as well as identifying combinations that could potentially combat resistance to immunotherapy, Manochakian concludes.

Related Videos
Ivy Riano, MD, of Dartmouth Geisel School of Medicine
Daniel E. Haggstrom, MD
Daniel E. Haggstrom, MD
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss unmet needs and future research directions in ALK-positive and ROS1-positive NSCLC.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for lorlatinib in ROS1-positive NSCLC after crizotinib and chemotherapy.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for taletrectinib in ROS1-positive advanced non–small cell lung cancer.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, on progression patterns and subsequent therapies after lorlatinib in ALK-positive NSCLC.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss preclinical CNS data for the ROS1 inhibitor zidesamtinib.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for zidesamtinib in ROS1-positive non–small cell lung cancer.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for NVL-655 in ALK-positive NSCLC and other ALK-positive solid tumors.